Skip to content

Warner & Kaine Join Senate Colleagues in Urging Continued Action to Address IV Fluid Shortage Amidst Hurricane Recovery

WASHINGTON, D.C. – U.S. Senators Mark R. Warner and Tim Kaine (both D-VA) joined Senators Mark Kelly (D-AZ), Kyrsten Sinema (I-AZ), and Bob Casey (D-PA) in sending a letter to Secretary of Health and Human Services (HHS) Xavier Becerra urging continued action to address the critical intravenous (IV) fluid shortage affecting hospitals across the nation. This shortage, caused by the temporary closure of Baxter International's manufacturing plant in North Carolina due to flooding from Hurricane Helene, has created significant challenges for health care providers in Virginia and across the country. 

The senators’ letter comes in response to the production halt at Baxter International, the largest manufacturer of intravenous (IV) solutions in the United States, which produces nearly two-thirds of the IV fluids used in U.S. hospitals. While federal agencies—including the HHS, the Food and Drug Administration (FDA), and the Administration for Strategic Preparedness and Response (ASPR)—work to increase supply from other manufacturers, allow temporary importation of products manufactured abroad, and provide guidance on compounded alternatives, hospitals across the country, including in Virginia, continue to face shortages and need clear communication to effectively plan for the months ahead. The letter emphasized that the federal response must especially prioritize providers whose patient communities will be most at risk in the face of continued shortages. 

“The uncertainty created by reduced product deliveries has led to conservation policies in health facilities across our states. After orders were recently cancelled, some providers have reported having only single-digit days’ worth of product on hand, while others are utilizing over the-counter oral hydration solutions like Gatorade—and fear reduced allocations of those alternatives as well. While providers are seeing promising results from HHS’s actions so far, we must ensure this progress continues,” wrote the senators.  

“As you take the necessary steps to increase production of IV products at alternative domestic sites, facilitate the expedited arrival of additional product from overseas, and review product shelf life to consider extensions, we ask you provide clear and continuous communication to health providers on their options and the path forward as communities recover from this storm and any impact that may stem from Hurricane Milton,” the senators concluded.

Read the full letter to Secretary Becerra here and below:

Dear Secretary Becerra:

We appreciate the Biden Administration’s efforts to swiftly respond to the catastrophic damage caused across the southeast by Hurricane Helene. As you continue this recovery work, on behalf of our constituents and the health care providers who serve them, we write to urge you to continue to work with hospital and health system partners to address disruptions in the intravenous (IV) solution supply chain resulting from the hurricane-induced closure of the Baxter International plant in North Cove, North Carolina.

As you know, Baxter is the largest manufacturer of IV solutions in the United States. Their facility in Western North Carolina produces nearly two-thirds of the IV solution used to provide health care nationwide. As you also know, to protect from stockpiling, Baxter has instituted limits on the amount of saline solution and dextrose product hospitals and health systems are currently able to order. We are encouraged by steps taken by your agency and other federal government agencies to move product more quickly, including rebuilding physical infrastructure, working with manufacturing partners to increase supply from other sites, and providing guidance on appropriate compounding.

However, the uncertainty created by reduced product deliveries has led to conservation policies in health facilities across our states. After orders were recently canceled, some providers have reported having only single-digit days’ worth of product on hand, while others are utilizing over-the-counter oral hydration solutions like Gatorade—and fear reduced allocations of those alternatives as well. While providers are seeing promising results from HHS’s actions so far, we must ensure this progress continues.

As you take the necessary steps to increase production of IV products at alternative domestic sites, facilitate the expedited arrival of additional product from overseas, and review product shelf life to consider extensions, we ask you provide clear and continuous communication to health providers on their options and the path forward as communities recover from this storm and any impact that may stem from Hurricane Milton. We also request intentional outreach to safety net, tribal, and rural providers, as well as those caring for vulnerable populations who may lack the resources to sustain prolonged shortages. Hospitals and health systems in our states are eager to work with you to protect patient care and welcome your outreach.

We look forward to working with you to ensure timely and robust communication to keep our communities healthy. Thank you for your attention to this matter.

Sincerely,

###